Potential clinical biomarkers and perspectives in diabetic cardiomyopathy

Area of Science:

• Cardiology
• Endocrinology
• Biomarker Discovery

Background:

• Diabetic cardiomyopathy (DCM) is a major cause of mortality in diabetic patients.
• Early DCM stages are often asymptomatic with normal cardiac function, hindering timely diagnosis.
• Current clinical markers lack specificity for early DCM detection.

Purpose of the Study:

• To review current knowledge on diabetic cardiomyopathy biomarkers.
• To identify novel biomarkers for early DCM diagnosis and management.
• To explore pathophysiologic mechanisms for improved DCM treatment strategies.

Main Methods:

• Literature review of recent studies on DCM biomarkers.
• Analysis of novel markers including galectin-3 (Gal-3), adiponectin (APN), and irisin.
• Synthesis of current findings to guide future research.

Main Results:

• Gal-3, APN, and irisin exhibit significant changes during DCM progression.
• These novel markers suggest potential for improved early DCM identification.
• Existing markers are insufficient for specific early DCM diagnosis.

Conclusions:

• Early detection of DCM is critical to reduce mortality.
• Novel biomarkers like Gal-3, APN, and irisin offer hope for early DCM diagnosis.
• Further research into these biomarkers and their mechanisms is warranted for effective DCM management.